These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 33457075)

  • 1. Anti-NKG2D single domain-based antibodies for the modulation of anti-tumor immune response.
    Raynaud A; Desrumeaux K; Vidard L; Termine E; Baty D; Chames P; Vigne E; Kerfelec B
    Oncoimmunology; 2020 Dec; 10(1):1854529. PubMed ID: 33457075
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bispecific antibody-mediated redirection of NKG2D-CAR natural killer cells facilitates dual targeting and enhances antitumor activity.
    Zhang C; Röder J; Scherer A; Bodden M; Pfeifer Serrahima J; Bhatti A; Waldmann A; Müller N; Oberoi P; Wels WS
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599028
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bispecific killer cell engagers employing species cross-reactive NKG2D binders redirect human and murine lymphocytes to ErbB2/HER2-positive malignancies.
    Pfeifer Serrahima J; Schoenfeld K; Kühnel I; Harwardt J; Macarrón Palacios A; Prüfer M; Kolaric M; Oberoi P; Kolmar H; Wels WS
    Front Immunol; 2024; 15():1457887. PubMed ID: 39267747
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The NKG2D/NKG2DL Axis in the Crosstalk Between Lymphoid and Myeloid Cells in Health and Disease.
    Stojanovic A; Correia MP; Cerwenka A
    Front Immunol; 2018; 9():827. PubMed ID: 29740438
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Leveraging NKG2D Ligands in Immuno-Oncology.
    Fuertes MB; Domaica CI; Zwirner NW
    Front Immunol; 2021; 12():713158. PubMed ID: 34394116
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Natural killer group 2D receptor and its ligands in cancer immune escape.
    Duan S; Guo W; Xu Z; He Y; Liang C; Mo Y; Wang Y; Xiong F; Guo C; Li Y; Li X; Li G; Zeng Z; Xiong W; Wang F
    Mol Cancer; 2019 Feb; 18(1):29. PubMed ID: 30813924
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Arming cytotoxic lymphocytes for cancer immunotherapy by means of the NKG2D/NKG2D-ligand system.
    Lazarova M; Wels WS; Steinle A
    Expert Opin Biol Ther; 2020 Dec; 20(12):1491-1501. PubMed ID: 32726145
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual Targeting of Glioblastoma Cells with Bispecific Killer Cell Engagers Directed to EGFR and ErbB2 (HER2) Facilitates Effective Elimination by NKG2D-CAR-Engineered NK Cells.
    Kiefer A; Prüfer M; Röder J; Pfeifer Serrahima J; Bodden M; Kühnel I; Oberoi P; Wels WS
    Cells; 2024 Jan; 13(3):. PubMed ID: 38334638
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel NKG2D-directed bispecific antibodies enhance antibody-mediated killing of malignant B cells by NK cells and T cells.
    Lutz S; Klausz K; Albici AM; Ebinger L; Sellmer L; Teipel H; Frenzel A; Langner A; Winterberg D; Krohn S; Hust M; Schirrmann T; Dübel S; Scherließ R; Humpe A; Gramatzki M; Kellner C; Peipp M
    Front Immunol; 2023; 14():1227572. PubMed ID: 37965326
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting NKG2D/NKG2DL axis in multiple myeloma therapy.
    Liu Z; Wang H; Liu H; Ding K; Shen H; Zhao X; Fu R
    Cytokine Growth Factor Rev; 2024 Apr; 76():1-11. PubMed ID: 38378397
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bispecific NKG2D-CD3 and NKG2D-CD16 fusion proteins for induction of NK and T cell reactivity against acute myeloid leukemia.
    Märklin M; Hagelstein I; Koerner SP; Rothfelder K; Pfluegler MS; Schumacher A; Grosse-Hovest L; Jung G; Salih HR
    J Immunother Cancer; 2019 May; 7(1):143. PubMed ID: 31142382
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heat-killed Helicobacter pylori upregulates NKG2D ligands expression on gastric adenocarcinoma cells via Toll-like receptor 4.
    Hernández C; Toledo-Stuardo K; García-González P; Garrido-Tapia M; Kramm K; Rodríguez-Siza JA; Hermoso M; Ribeiro CH; Molina MC
    Helicobacter; 2021 Aug; 26(4):e12812. PubMed ID: 33928707
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The NKG2D axis: an emerging target in cancer immunotherapy.
    Lazarova M; Steinle A
    Expert Opin Ther Targets; 2019 Apr; 23(4):281-294. PubMed ID: 30732494
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fc-optimized NKG2D-Fc constructs induce NK cell antibody-dependent cellular cytotoxicity against breast cancer cells independently of HER2/neu expression status.
    Raab S; Steinbacher J; Schmiedel BJ; Kousis PC; Steinle A; Jung G; Grosse-Hovest L; Salih HR
    J Immunol; 2014 Oct; 193(8):4261-72. PubMed ID: 25217158
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Soluble ligands for the NKG2D receptor are released during HIV-1 infection and impair NKG2D expression and cytotoxicity of NK cells.
    Matusali G; Tchidjou HK; Pontrelli G; Bernardi S; D'Ettorre G; Vullo V; Buonomini AR; Andreoni M; Santoni A; Cerboni C; Doria M
    FASEB J; 2013 Jun; 27(6):2440-50. PubMed ID: 23395909
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activated NK cells reprogram MDSCs via NKG2D-NKG2DL and IFN-γ to modulate antitumor T-cell response after cryo-thermal therapy.
    Peng P; Lou Y; Wang S; Wang J; Zhang Z; Du P; Zheng J; Liu P; Xu LX
    J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36521929
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting NKG2DL with Bispecific NKG2D-CD16 and NKG2D-CD3 Fusion Proteins on Triple-Negative Breast Cancer.
    Kaidun P; Holzmayer SJ; Greiner SM; Seller A; Tegeler CM; Hagelstein I; Mauermann J; Engler T; Koch A; Hartkopf AD; Salih HR; Märklin M
    Int J Mol Sci; 2023 Aug; 24(17):. PubMed ID: 37685962
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Generation, affinity maturation, and characterization of a human anti-human NKG2D monoclonal antibody with dual antagonistic and agonistic activity.
    Kwong KY; Baskar S; Zhang H; Mackall CL; Rader C
    J Mol Biol; 2008 Dec; 384(5):1143-56. PubMed ID: 18809410
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An Fc-optimized NKG2D-immunoglobulin G fusion protein for induction of natural killer cell reactivity against leukemia.
    Steinbacher J; Baltz-Ghahremanpour K; Schmiedel BJ; Steinle A; Jung G; Kübler A; André MC; Grosse-Hovest L; Salih HR
    Int J Cancer; 2015 Mar; 136(5):1073-84. PubMed ID: 25046567
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human IgG1 antibodies antagonizing activating receptor NKG2D on natural killer cells.
    Steigerwald J; Raum T; Pflanz S; Cierpka R; Mangold S; Rau D; Hoffmann P; Kvesic M; Zube C; Linnerbauer S; Lumsden J; Sriskandarajah M; Kufer P; Baeuerle PA; Volkland J
    MAbs; 2009; 1(2):115-27. PubMed ID: 20061825
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.